CL Stock Analysis: Colgate-Palmolive | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 74.265m USD | 12M Return: 33.1% | US1941621039 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 427M
EPS Trend: 95.1%
Qual. Beats: 15
Rev. Trend: 91.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Colgate-Palmolive Company (NYSE: CL) is a global consumer products manufacturer founded in 1806 and headquartered in New York. It operates through two segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care segment produces toothpaste, toothbrushes, hand soaps, shampoos, deodorants, dishwashing detergents, household cleaners, and skin health products, marketed under brands such as Colgate, Palmolive, Toms of Maine, Irish Spring, Softsoap, Ajax, and Fabuloso. The Pet Nutrition segment offers everyday and therapeutic pet foods primarily under the Hills Science Diet and Hills Prescription Diet brands, distributed through pet supply retailers, veterinarians, and eCommerce channels.
As a large-cap Consumer Staples company in the Household Products sub-industry, Colgate-Palmolive competes in a defensive sector typically characterized by stable demand across economic cycles. Its business model centers on a diversified portfolio of established global brands, broad international distribution, and recurring purchases of low-priced essential goods such as oral care, cleaning, and pet nutrition products.
- Hills Pet Nutrition outpaces oral care segment growth
- Latin America FX headwinds pressure reported revenue
- Premium skincare acquisitions lift gross margins
| Net Income: 2.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 2.97 > 1.0 |
| NWC/Revenue: -1.32% < 20% (prev -2.27%; Δ 0.95% < -1%) |
| CFO/TA 0.26 > 3% & CFO 4.37b > Net Income 2.05b |
| Net Debt (6.75b) to EBITDA (3.86b): 1.75 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (799.0m) vs 12m ago -1.38% < -2% |
| Gross Margin: 60.61% > 18% (prev 60.15%; Δ 0.46% > 0.5%) |
| Asset Turnover: 124.3% > 50% (prev 114.7%; Δ 9.52% > 0%) |
| Interest Coverage Ratio: 12.87 > 6 (EBIT TTM 3.22b / Interest Expense TTM 250.0m) |
| A: -0.02 (Total Current Assets 6.36b - Total Current Liabilities 6.64b) / Total Assets 16.7b |
| B: 1.64 (Retained Earnings 27.4b / Total Assets 16.7b) |
| C: 0.19 (EBIT TTM 3.22b / Avg Total Assets 17.1b) |
| D: 0.02 (Book Value of Equity 288.0m / Total Liabilities 16.1b) |
| Altman-Z'' = 6.51 = AAA |
| DSRI: 0.99 (Receivables 1.90b/1.81b, Revenue 21.3b/20.1b) |
| GMI: 0.99 (GM 60.15% / 60.61%) |
| AQI: 0.87 (AQ_t 0.34 / AQ_t-1 0.39) |
| SGI: 1.06 (Revenue 21.3b / 20.1b) |
| TATA: -0.14 (NI 2.05b - CFO 4.37b) / TA 16.7b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of November 03, 2026, the stock is trading at USD 97.43 with a total of 5,078,451 shares traded. Over the past week, the price has changed by +4.65%, over one month by +16.29%, over three months by +9.02% and over the past year by +33.06%.
Current recommended Stop Loss: 93.50 (which is 4% or 1.9 ATR below the current price).
Colgate-Palmolive has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy CL.
- StrongBuy: 7
- Buy: 6
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 98.2 | 0.7% |
P/E Trailing = 36.6772
P/E Forward = 22.3714
P/S = 3.5285
P/B = 309.7152
P/EG = 1.6709
Revenue TTM = 21.3b USD
EBIT TTM = 3.22b USD
EBITDA TTM = 3.86b USD
Long Term Debt = 6.87b USD (from longTermDebt, last fiscal year)
Short Term Debt = 532.0m USD (from shortTermDebt, last quarter)
Debt = 8.28b USD (from shortLongTermDebtTotal, last quarter) + Leases 566.0m
Net Debt = 6.75b USD (calculated: Debt 8.28b - CCE 1.53b)
Enterprise Value = 81.0b USD (74.3b + Debt 8.28b - CCE 1.53b)
Interest Coverage Ratio = 12.87 (Ebit TTM 3.22b / Interest Expense TTM 250.0m)
EV/FCF = 21.38x (Enterprise Value 81.0b / FCF TTM 3.79b)
FCF Yield = 4.68% (FCF TTM 3.79b / Enterprise Value 81.0b)
FCF Margin = 17.80% (FCF TTM 3.79b / Revenue TTM 21.3b)
Net Margin = 9.65% (Net Income TTM 2.05b / Revenue TTM 21.3b)
Gross Margin = 60.61% ((Revenue TTM 21.3b - Cost of Revenue TTM 8.38b) / Revenue TTM)
Gross Margin QoQ = 60.22% (prev 61.48%)
Tobins Q-Ratio = 4.84 (Enterprise Value 81.0b / Total Assets 16.7b)
Interest Expense / Debt = 3.02% (Interest Expense 250.0m / Debt 8.28b)
Taxrate = 26.75% (794.0m / 2.97b)
NOPAT = 2.36b (EBIT 3.22b * (1 - 26.75%))
Current Ratio = 0.96 (Total Current Assets 6.36b / Total Current Liabilities 6.64b)
Debt / Equity = 28.76 (Debt 8.28b / totalStockholderEquity, last quarter 288.0m)
Debt / EBITDA = 1.75 (Net Debt 6.75b / EBITDA 3.86b)
Debt / FCF = 1.78 (Net Debt 6.75b / FCF TTM 3.79b)
Total Stockholder Equity = 258.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.99% (Net Income 2.05b / Total Assets 16.7b)
RoE = 794.2% (Net Income TTM 2.05b / Total Stockholder Equity 258.5m)
RoCE = 45.14% (EBIT 3.22b / Capital Employed (Equity 258.5m + L.T.Debt 6.87b))
RoIC = 24.63% (NOPAT 2.36b / Invested Capital 9.57b)
WACC = 4.48% (E(74.3b)/V(82.5b) * Re(4.73%) + D(8.28b)/V(82.5b) * Rd(3.02%) * (1-Tc(0.27)))
Discount Rate = 4.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.53 | Cagr: -1.34%
[DCF] Terminal Value 76.67% ; FCFF base≈3.65b ; Y1≈3.97b ; Y5≈4.93b
[DCF] Fair Price = 86.24 (EV 75.5b - Net Debt 6.75b = Equity 68.7b / Shares 797.2m; r=8.35% [WACC [floored]]; 5y FCF grow 10.05% → 2.50% )
EPS Correlation: 95.11 | EPS CAGR: 5.61% | SUE: 4.0 | # QB: 15
Revenue Correlation: 91.12 | Revenue CAGR: 2.70% | SUE: 0.66 | # QB: 0
EPS current Year (2026-12-31): EPS=3.87 | Chg30d=-0.17% | Revisions=-50% | GrowthEPS=+4.8% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=4.09 | Chg30d=-0.32% | Revisions=-62% | GrowthEPS=+5.7% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: -73% (up=0, down=8)